Two internationally known scholars, one in the field of cancer prevention and the other in the field of molecular biology, will join Huntsman Cancer Institute (HCI) at the University of Utah as early as September 1.
A national poll from the University of Utah's Huntsman Cancer Institute shows 34 percent of respondents would not seek genetic testing to predict their likelihood of developing a hereditary cancer - even if the cost of the testing was not an issue.
Cells with a mutation in the gene called K-Ras—found in close to 30% of all cancers, but mostly those with worst prognosis, such as pancreatic cancer, colon cancer, and lung cancer—behave in ways that subvert the normal mechanisms of cell death, according to a cell-culture study by researchers from Huntsman Cancer Institute (HCI) at the University of Utah.
For the past ten years, clinicians throughout the United States have been performing unnecessary Pap tests for cervical cancer screening in certain groups of women, according to a researcher from Huntsman Cancer Institute (HCI) at the University of Utah.
At a time when the incidence and prevalence of cancers in all age groups—including children—is increasing, and funding for cancer research is on the decline, officials at Huntsman Cancer Institute at the University of Utah today announced a plan to expand HCI’s research capabilities—a new, 220,000-square-foot addition.
CureSearch for Children's Cancer this week awarded researchers at Huntsman Cancer Institute at the University of Utah a $1.73 million grant to test a novel targeted treatment for Ewing sarcoma that hopefully will disrupt the cancer's growth and spread. If successful, their work could lead to new treatment for the more than 250 children diagnosed with this rare cancer each year.
The National Cancer Institute (NCI) has awarded Huntsman Cancer Institute investigator Matt VanBrocklin, Ph.D., more than $1.5 million over the next five years to continue studying the role of a gene called c-KIT in the origin and growth of melanoma, a devastating and sometimes deadly skin cancer. VanBrocklin is an assistant professor in the Department of Surgery at the University of Utah.
When a child is diagnosed with cancer, one of the first questions the parents ask is "Will my other children get cancer?" A new study from Huntsman Cancer Institute (HCI) at the University of Utah suggests the answer to that question depends on whether or not a family history of cancer exists. The research results were published online in the International Journal of Cancer and will appear in the November 15 print issue.
Researchers from Huntsman Cancer Institute (HCI) at the University of Utah have discovered that while the genes provided by the father arrive at fertilization pre-programmed to the state needed by the embryo, the genes provided by the mother are in a different state and must be reprogrammed to match. The findings have important implications for both developmental biology and cancer biology.
Researchers from Huntsman Cancer Institute (HCI) at the University of Utah have developed a novel and powerful technique to identify the targets for a group of enzymes called RNA cytosine methyltransferases (RMTs) in human RNA. They applied their technique to a particular RMT, NSUN2, which has been implicated in mental retardation and cancers in humans, finding and validating many previously unknown RMT targets—an indication of the technique's power. The research results were published online in the journal Nature Biotechnology on April 21.
John Sweetenham, M.D., currently a Professor of Medicine at the University of California, San Diego, and Medical Director of the UCSD University of Nevada Cancer Institute, has been appointed Senior Director of Clinical Affairs and Executive Medical Director at Huntsman Cancer Institute (HCI), and Professor in the Department of Medicine, Division of Hematologic Oncology at the University of Utah after a national search. He will assume his post April 1.
People who reside in rural areas of Utah are less likely to follow colorectal cancer (CRC) screening recommendations than their urban counterparts, according to researchers from Huntsman Cancer Institute (HCI) at the University of Utah. This geographic disparity is evident across all risk groups, including those who have a family history of the disease.
HCI researchers were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic lymphoma (Ph+ ALL).
Discovery of a new drug with high potential to treat Ewing sarcoma, an often deadly cancer of children and young adults, and the previously unknown mechanism behind it, come hand-in-hand in a new study by researchers from Huntsman Cancer Institute (HCI) at the University of Utah. The report appears in today’s online issue of the journal Oncogene.
A new discovery from researchers at HCI concerning a fundamental understanding about how DNA works will produce a "180-degree change in focus" for researchers who study how gene packaging regulates gene activity, including genes that cause cancer and other diseases.
Many patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance." This can be a problem, as people with Lynch syndrome have a much higher probability to develop colon cancer, and often develop colon cancer at an earlier age than is common among the general population; consequently, they need to begin screening at a much younger age.